Plasma is the liquid portion of the blood. Plasma is the versatile component and makes about 55% of the blood. Plasma is the composite mixture of more than 700 proteins and other substances which are vital for the efficient functioning of the human body. Plasma helps in regulating body temperature and blood pressure. It serves as a medium for exchange of proteins, nutrients and hormones to the different parts of the body. Clotting factor, albumin and immunoglobulin are some of the major proteins found in plasma. Plasma is extracted as proteins and substances and used as main ingredients in medical products to replace body fluids, clotting factors and antibodies. Plasma is used as a component for the treatment of serious health problems such as hemophilia and autoimmune disorders.
North America dominates the global market for blood plasma due to large number of aging population. Asia followed by the Europe is expected to show high growth rates in the next five years in global blood plasma market. China is expected to be the fastest growing blood plasma markets in Asia region. Some of the key driving forces for blood plasma market in emerging countries are large pool of patients and rising government funding.
In recent times there is increased use of blood plasma due to increasing new patient registration for hemophilia treatment. Increasing health issues due to change in lifestyle, increased penetration of plasma derived products and rising healthcare expenditure are some of the key factors driving the growth for global blood plasma market. In addition, increasing aging population is also fuelling the growth of global blood plasma market. However, strict regulator requirement in plasma collection, misdiagnosis of disease and escalating price pressure are some of the major factors restraining the growth for global blood plasma market.
Advancement and changes in healthcare and biomedical technology develop opportunity for global blood plasma market. Some of the trends for global blood plasma market are rising penetration of episodic treatment in emerging markets and growth in U.S. immunoglobulin reimbursement. Some of the major companies operating in the global blood plasma market are Baxter International Inc., CSL Limited, Grifols and Octapharma AG.
Key points covered in the report
The report covers geographic segmentation